Is Ivosidenib covered by medical insurance?

Ivosidenib (Ivosidenib) is a targeted therapy drug used to treat acute myeloid leukemia (AML) and belongs to the drug class of IDH1 inhibitors.

Avosidenib is already on the market in China, but it has not yet been included in medical insurance. The price of Avosidenib on the domestic market is very high, reaching tens of thousands of yuan. For specific prices, please consult the local hospital pharmacy. The price of the American original drug of Ivonib abroad is as high as hundreds of thousands. Currently, there are generic drugs of Ivonib on the market, mainly Laos generic drugs, which cost about 10,000 yuan, which is much cheaper in comparison, and the ingredients of the original drug and the generic drug are basically the same.

The main effect of Ivonib is by specifically inhibiting the activity of isocitrate dehydrogenase1 (IDH1), an enzyme involved in cellular metabolism. In AML patients, some leukemia cells have mutations in the IDH1 gene, leading to abnormal activation of the IDH1 enzyme. The mechanism of action of ivonib is to regulate the metabolic process of leukemia cells by inhibiting the IDH1 enzyme, thereby slowing or stopping the growth and proliferation of leukemia cells.

Patients usually need to be tested for IDH1 gene mutations before receiving ivonib treatment to ensure that their genotype meets the indications of the drug. During treatment, doctors will develop a personalized medication plan and conduct regular monitoring to evaluate efficacy and safety.

Clinical trial data show that AML patients treated with ivonib showed a higher response rate and longer survival than the traditional treatment group. This makes ivonib a much-anticipated drug in the treatment of AML.

Although Ivonib has milder side effects than traditional chemotherapy drugs, patients still need to pay attention to possible discomforts during treatment, such as nausea, vomiting, fatigue, etc. In addition, the drug may cause electrocardiogram changes and liver function abnormalities, so regular monitoring is required during treatment.